Published in
Elsevier, The Lancet Oncology, 5(20), p. 686-700, 2019
DOI: 10.1016/s1470-2045(19)30082-8
Links
Tools
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
Journal article published in 2019 by
Karim Fizazi,
NamPhuong Tran,
Luis Fein,
Nobuaki Matsubara,
Alfredo Rodriguez-Antolin,
Boris Y. Alekseev,
Mustafa Özgüroğlu 
,
Dingwei Ye,
Giri Sulur,
Susan Feyerabend,
Yesenia Luna,
Andrew Protheroe,
Susan Li,
Suneel Mundle,
Kim N. Chi
,
Dingwei Ye,
Giri Sulur,
Susan Feyerabend,
Yesenia Luna,
Andrew Protheroe,
Susan Li,
Suneel Mundle,
Kim N. Chi
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 